Introduction
============

Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease of unknown etiology ([@b1-etm-0-0-8709]). IPF is associated with an increased fibroblast population, leading to excessive deposition of collagen in the lung alveolar spaces ([@b1-etm-0-0-8709],[@b2-etm-0-0-8709]). This pathological change subsequently leads to decreased gas exchange and respiratory failure. While disease progression is usually slow, a number of patients experience acute deterioration of respiratory function, which is termed as acute exacerbation (AE) of IPF (AE-IPF) ([@b2-etm-0-0-8709]). In a retrospective review of 461 patients with IPF in South Korea, the 1- and 3-year incidences of AE-IPF were estimated to be 14.2 and 20.7%, respectively ([@b3-etm-0-0-8709]). While the exact etiology of AE-IPF remains elusive, the prognosis is poor, with a systematic review estimating the mortality rate to be 60% at 1 month and 67% at 3 months after disease onset ([@b4-etm-0-0-8709]).

The pathophysiology of AE-IPF has been attributed to pro-coagulant and antifibrinolytic activity in affected patients ([@b3-etm-0-0-8709]). Imokawa *et al* ([@b5-etm-0-0-8709]) demonstrated the strong presence of tissue factor, a coagulation initiator, in the lung tissues of patients with IPF. Kotani *et al* ([@b6-etm-0-0-8709]) have reported higher concentrations of plasminogen activator inhibitor (PAI)-1 and PAI-2 antigen levels in bronchoalveolar lavage (BAL) supernatant fluids and cell lysates, suggestive of an antifibrinolytic activity. While one study corroborate this theory based on improved survival of patients treated with low-molecular-weight heparin ([@b7-etm-0-0-8709]), another study indicated a lack of benefit of anticoagulant therapy in such patients ([@b8-etm-0-0-8709]). High-dose corticosteroids and immunosuppressive drugs, including cyclosporine A, have also been used for managing AE-IPF, but the clinical efficacy of these drugs is still under dispute ([@b9-etm-0-0-8709],[@b10-etm-0-0-8709]).

Thrombomodulin, a transmembranous protein expressed on the surface of vascular endothelial cells, is an essential component in the regulation of intravascular coagulation ([@b11-etm-0-0-8709]). Due to its anticoagulant and anti-inflammatory effects, thrombomodulin has been successfully used in the management of disseminated intravascular coagulation (DIC) ([@b11-etm-0-0-8709]). Recombinant human soluble thrombomodulin (rhTM; Recomodulin; Asahi Kasei Pharma Corp.), which comprises only the extracellular domain of thrombomodulin, has also been explored in the management of various respiratory, renal and cardiovascular diseases ([@b12-etm-0-0-8709]). Recently, several trials reported on the use of rhTM in the management of AE-IPF ([@b13-etm-0-0-8709]). While research is still at the nascent stage, there is a requirement to summarize the results of these multiple studies to evaluate the quality of evidence and provide a direction for further research. Therefore, the purpose of the present systematic review and meta-analysis was to evaluate the efficacy and safety of rhTM when used in the management of AE-IPF.

Materials and methods
=====================

### Guidelines

The guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses ([@b16-etm-0-0-8709]) and the Cochrane Handbook for Systematic Reviews of Intervention ([@b17-etm-0-0-8709]) were followed during the preparation of this review.

### Search strategy

An electronic search of titles and abstracts in the PubMed (<https://pubmed.ncbi.nlm.nih.gov>), Biomed Central (<https://www.biomedcentral.com>), Scopus (<https://www.scopus.com/home.uri>) and Embase (<https://www.embase.com/login#search>) databases was performed using the following key words: 'Recombinant human thrombomodulin', 'thrombomodulin', 'pulmonary fibrosis', 'AE', 'IPF' and 'clinical outcomes'. Titles were searched by two independent reviewers (BW and TL) with the last search performed on 31st August 2019. The reference lists of published studies and review articles on the subject were also searched for the identification of any further trials. After screening records by their titles and abstracts, the full texts of selected articles were retrieved. Each of the two reviewers assessed individual studies based on the inclusion criteria. Disagreements, if any, were resolved by discussion.

### Study selection and outcomes

Using the common evidence medicine framework, population, intervention, comparison, outcome ([@b18-etm-0-0-8709]), all types of studies performed on patients with AE-IPF (*Population*) were included. Trials comparing rhTM (*Intervention*) vs. control (*Comparison*) for AE-IPF and assessing mortality and adverse events (*Outcomes*) were included in the review. Duplicate studies based on the same dataset, non-comparative studies, case series, case reports, review articles and studies that were not published in English language were excluded. In the case of studies with overlapping datasets, the study encompassing the largest dataset was selected.

Two independent reviewers retrieved data from selected studies using a standardized data collection form. The details sourced were the following: Authors, publication year, country of origin, sample size, baseline characteristics of study participants, treatment protocol, mortality and adverse events. The primary outcome of interest was the incidence of 28- and 90- day mortality. The secondary outcome was the incidence of adverse events.

### Risk of bias assessment

The Risk of Bias Assessment Tool for Non-randomized Studies was used for quality assessment ([@b19-etm-0-0-8709]). Studies were rated as having low, high or unclear risk of bias regarding the following points: Selection of participants, confounding variables, measurement of exposure blinding of outcome assessment, incomplete outcome data and selective outcome reporting.

### Statistical analysis

RevMan version 5.3 (Cochrane Collaboration) was used for meta-analysis. Considering the methodological heterogeneity amongst studies, a random-effects model was used to calculate the pooled effect size. Data were summarised using the Mantel-Haenszel odds ratio (OR) with 95% CI. Inter-study heterogeneity was estimated using the I^2^ statistic. I^2^ values of 25-50% were considered to indicate low heterogeneity, 50-75% medium heterogeneity and \>75% represented substantial heterogeneity.

Results
=======

### Literature search and study selection

The literature search yielded a total of 85 records. After the exclusion of duplicates, 30 unique articles were identified. The titles and abstracts of these 30 articles were then screened for possible inclusion in the present study. A total of 22 articles were excluded due to non-relevance and full texts of 8 articles were retrieved ([Fig. 1](#f1-etm-0-0-8709){ref-type="fig"}). A total of three studies ([@b19-etm-0-0-8709]) had overlapping datasets, of which two ([@b20-etm-0-0-8709],[@b21-etm-0-0-8709]) were excluded. A total of six studies ([@b13-etm-0-0-8709], [@b21-etm-0-0-8709]) were finally included in the present systematic review and meta-analysis.

### Features of the studies included

Details of the studies included are presented in [Table I](#tI-etm-0-0-8709){ref-type="table"}. Two studies were retrospective studies ([@b13-etm-0-0-8709],[@b22-etm-0-0-8709]) and three were single-arm prospective studies utilizing a historical control group ([@b14-etm-0-0-8709],[@b15-etm-0-0-8709],[@b23-etm-0-0-8709]), while one was a non-randomized prospective trial ([@b24-etm-0-0-8709]). All trials were performed in Japan. The sample size varied across the studies, with 6-61 participants per group. The baseline parameters of the experimental and control groups as reported by the studies are presented in [Table II](#tII-etm-0-0-8709){ref-type="table"}. The authors reported negligible differences in the baseline parameters between the rhTM and control groups. The dosage of rhTM was the same across the studies (0.06 mg/kg/day is equivalent to 380 U/kg/day). Methylprednisolone pulse therapy was administered for three days in all studies in the experimental and control groups.

### Outcomes

The 28-day mortality rates were reported by three studies ([@b14-etm-0-0-8709],[@b15-etm-0-0-8709],[@b24-etm-0-0-8709]). Within the rhTM group, 29.26% of patients died, while 56.66% of patients died in the control group. The meta-analysis indicated that treatment with rhTM was associated with a significant reduction in 28-day mortality compared with that in the control group (OR, 0.25; 95% CI, 0.08-0.77; P=0.02; I^2^=0%; [Fig. 2](#f2-etm-0-0-8709){ref-type="fig"}).

The 90-day mortality rates were reported by five ([@b13-etm-0-0-8709],[@b14-etm-0-0-8709],[@b21-etm-0-0-8709]) of the six studies included. A total of 125 patients received rhTM, while 140 patients served as controls. The overall 90-day mortality rate was 33.6% in the rhTM group and 62.85% in the control group. Pooled analysis indicated that rhTM significantly reduced the 90-day mortality in patients with AE-IPF (OR, 0.29; 95% CI, 0.17-0.49; P\<0.00001; I^2^=0%; [Fig. 3](#f3-etm-0-0-8709){ref-type="fig"}).

Data on adverse events were reported by five trials ([@b13-etm-0-0-8709],[@b14-etm-0-0-8709],[@b21-etm-0-0-8709]). Details of adverse events in the studies included are presented in [Table III](#tIII-etm-0-0-8709){ref-type="table"}. Hayakawa *et al* ([@b14-etm-0-0-8709]) did not report any adverse events, while Sakamoto *et al* ([@b22-etm-0-0-8709]) reported only minor adverse events in the study group, which did not require discontinuation of treatment. Abe *et al* ([@b24-etm-0-0-8709]) reported one case of hepatic and renal failure in the study group. The authors suspected the cause of death in this patient to be a drug interaction between warfarin and cyclosporine, leading to uncontrolled serum levels of cyclosporine and subsequent renal and hepatic failure. Kataoka *et al* ([@b13-etm-0-0-8709]) reported hemorrhagic complications in the study and control groups, which were managed by discontinuation of rhTM and low-molecular-weight heparin, respectively. Arai *et al* ([@b23-etm-0-0-8709]) reported two cases of bleeding (1 case of gastrointestinal and 1 case of nasal) in the control group but no hemorrhagic complication in the rhTM group. All adverse events were pooled for a meta-analysis, which demonstrated no significant difference between the rhTM and control groups (OR, 1.07; 95% CI, 0.45-2.51; P=0.88; I^2^=0%; [Fig. 4](#f4-etm-0-0-8709){ref-type="fig"}).

### Risk of bias

The assessment of the risk of bias in the included studies is presented in [Table IV](#tIV-etm-0-0-8709){ref-type="table"}. A high risk of bias was noted across all studies in the selection of participants, which were recruited at different time intervals in all trials.

Discussion
==========

Several different therapies have been studied to improve outcomes in AE-IPF. These include corticosteroids, anticoagulants, antacids, ambrisentan, imatinib, nintedanib, phosphodiesterase-5 inhibitors, pirfenidone, dual endothelin receptor antagonists (e.g. macitentan) and combination therapy of prednisone, azathioprine and N-acetylcysteine ([@b25-etm-0-0-8709]). Despite several attempted treatment strategies, no single management protocol has been accepted as the standard to date. The updated American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society guidelines do not recommend the use of warfarin, ambrisentan, imatinib or the combination therapy of prednisone, azathioprine and N-acetylcysteine, while providing a conditional recommendation for nintedanib, pirfenidone, macitentan and phosphodiesterase-5 inhibitors ([@b25-etm-0-0-8709]).

The use of immunosuppressants, including cyclo-phosphamides, cyclosporine or tacrolimus, has been examined, but only in small retrospective studies providing inconclusive evidence for the potential benefits of these drugs ([@b9-etm-0-0-8709],[@b26-etm-0-0-8709]). In routine practice, administration of corticosteroids in the form of methylprednisolone pulse therapy is the most commonly employed management technique, despite low evidence supporting its use ([@b27-etm-0-0-8709]). Corticosteroid therapy was utilized in all six of the included studies of the present review but with disparity in the use of immunosuppressant drugs. Cyclophosphamide and/or cyclosporine were administered in three studies in the experimental and control groups, while in the clinical trial by Hayakawa *et al* ([@b14-etm-0-0-8709]), only the control group received immunosuppressants. The variance in the treatment strategies for AE-IPF may be attributed to the poorly understood pathophysiological mechanism of the disease.

In an attempt to elucidate the underlying pathology of AE, Collard *et al* ([@b28-etm-0-0-8709]) compared the plasma biomarker profiles between patients with AE-IPF, acute lung injury and stable IPF. The results indicated a significant increase in the levels of type II alveolar epithelial cell injury/proliferation markers \[Krebs von den Lungen-6 (KL-6) and surfactant protein D\], endothelial cell injury markers (von Willebrand factor), inflammation markers (interleukin-6) and coagulation markers (protein C, thrombomodulin and PAI-1) in patients with AE-IPF. Kataoka *et al* ([@b13-etm-0-0-8709]) detected high levels of D-dimer and thrombomodulin in BAL fluid from patients with AE-IPF. Song *et al* ([@b3-etm-0-0-8709]) reported that increased levels of C-reactive protein are a poor prognostic factor for AE-IPF. These studies suggested that dysfunction of endothelial cells, coagulation abnormalities and inflammation have an important role in the pathophysiology of AE-IPF.

The dual anticoagulant and antiinflammatory action of rhTM has been utilized in the management of AE-IPF ([@b13-etm-0-0-8709]). rhTM activates protein C by the formation of reversible complexes with thrombin. These complexes inactivate coagulation factors, thereby downregulating intravascular coagulation ([@b23-etm-0-0-8709]). Inflammation is also suppressed by inhibition of neutrophil adhesion, improved endothelial barrier function, decreased complement activation and expression of inflammatory cytokines, inactivation of bradykinin C3a and C5a and increased high-mobility group box-1 degradation ([@b12-etm-0-0-8709],[@b29-etm-0-0-8709]).

Following a systematic literature search, six unique studies evaluating the efficacy and safety of rhTM in AE-IPF were identified. The dose of rhTM was the same across studies (0.06 mg/kg/day is equivalent to 380 U/kg/day) ([@b30-etm-0-0-8709]). All studies utilized a 6-day drug protocol with the exception of one study ([@b14-etm-0-0-8709]), in which the drug was administered for seven days. With the limited evidence, the difference between the 6- and 7-day rhTM protocol remains to be determined. After pooling the data of 145 patients in the study group and 146 patients in the control group, the present results indicated that administration of rhTM decreased the 90-day mortality by 71% (CI, 51-83%) compared with that in patients who were not treated with the drug. Similarly, the 28-day mortality was reduced by 75% (CI, 23-92%) with the administration of rhTM, albeit with a large CI, probably due to the small number of studies with limited sample size included in the present analysis. The results of the present study are similar to a recently published meta-analysis of Kamiya *et al* ([@b31-etm-0-0-8709]). In their analysis of four studies, the authors noted a statistical significant difference in 90 day mortality with the use of rhTM in AE-IPF. However, due to fewer studies, no meta-analysis was conducted for 28 day mortality in their study.

The survival rate in the control arm of the present analysis was similar to that in studies utilizing only corticosteroid therapy for the management of AE-IPF ([@b3-etm-0-0-8709],[@b4-etm-0-0-8709]). It is important to note that to date, no randomized controlled trial (RCT) has been performed and the present review is a pooled analysis of non-randomized studies. The absence of randomization potentially introduces bias due to the presence of confounding factors. Mortality in AE-IPF may be dependent on several confounding factors, including disease severity, oxygen partial pressure/fraction of inspired oxygen ratio, D-dimer and KL-6 levels, high-resolution computed tomography (HRCT) pattern (diffuse/non-diffuse) and use of concomitant therapies, including anticoagulants and immunosuppressants ([@b3-etm-0-0-8709],[@b4-etm-0-0-8709]). While multivariate regression analysis performed in the clinical trials by Arai *et al* ([@b23-etm-0-0-8709]) and Sakamoto *et al* ([@b22-etm-0-0-8709]) indicated that rhTM independently improved the 90-day survival in patients with AE-IPF, the absence of robust RCTs diminishes the overall level of evidence.

Data from the post-marketing surveillance of rhTM therapy in patients with DIC demonstrated an incidence of all adverse events of 7.1%, with bleeding and serious bleeding complication rates of 5.5 and 6.8%, respectively ([@b32-etm-0-0-8709]). With similar rates of adverse events in the study (8.8%) and control groups (10%), the present results indicated rhTM to be safe in the management of AE-IPF. None of the included studies reported any serious bleeding events during the treatment with rhTM.

The following limitations should be considered when interpreting the results of the present review. First, as mentioned above, no RCTs were available for inclusion in the present review. The majority of the included studies used a historical control group for which the diagnosis and treatment protocols would have differed. In spite of the authors reporting baseline similarity amongst the study groups, certain confounding factors may have introduced bias in the overall results. Furthermore, the inherent limitations of included studies, e.g. methodological variation, limited sample size and differences in the use of adjunctive therapies, including anticoagulants, immunosuppressants, antibiotics and high-flow oxygen, may have led to skewed results. As another limitation, BAL and HRCT were not rigorously utilized for diagnostic purposes in all studies included. In addition, the difference in general supportive care amongst studies, as well as between the experimental and control groups, may have influenced the results. In addition, it was not possible to pool data other than those of mortality and adverse events in the present meta-analysis. The lack of evaluation of other clinical outcomes in the included studies restricted the present meta-analysis to these variables only. Finally, all studies were reported from a single country. The influence of the region and ethnicity on clinical outcomes requires to be considered.

In conclusion, bearing in mind the limitations our systematic review and meta-analysis, our results indicated that rhTM may improve the short-term mortality in patients with AE-IPF. The drug appears to be safe without any enhanced risk of adverse events. There is a requirement for high-quality RCTs with a large sample size to provide robust evidence supporting its use.
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###### 

Characteristics of included studies.

                                                                   Sample size   Age (years)                                                                                                                                                                                                                                                                                                                                                           
  ------------------------- -------------------------------------- ------------- ------------- ---------- ----------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Tsushima *et al* (2014)   Prospective with historical controls   20            6             76.2±0.4   73.7±1.2    rhTM group: MP pulse therapy at 1 g/day for 3 days, followed by prednisolone 1 mg/kg/day. rhTM (0.06 mg/kg/day) for 6 days. Control group: Similar treatment without rhTM.                                                                                                                                                       ([@b15-etm-0-0-8709])
  Kataoka *et al* (2015)    Retrospective                          20            20            73.5±NR    71.0±NR     rhTM group: MP pulse therapy at 1 g/day for 3 days with cyclosporine A 2.5 mg/kg/day followed by tapered dose of steroids. rhTM (0.06 mg/kg/day) for 6 days followed by continuous IV infusion of LMWH 750.000 IU/kg/day. LMWH discontinued if any adverse events were observed. Control group: Similar treatment without rhTM   ([@b13-etm-0-0-8709])
  Abe *et al* 2015)         Prospective, non-randomized            11            11            68.9±7.3   73.1±11.3   rhTM group: MP pulse therapy at 1 g/day for 3 days with cyclophosphamide and/or cyclosporine A and 0.06 mg/kg/day rhTM for 6 days. Control group: Similar treatment without rhTM.                                                                                                                                                ([@b24-etm-0-0-8709])
  Hayakawa *et al* (2016)   Prospective with historical controls   10            13            73.2±9.5   69.7±8.5    rhTM group: MP pulse therapy at 1 g/day for 3 days, then 80 mg/day for 7 days with rhTM 380 U/kg/day for 30 min for 7 days. Concomitant administration of anticoagulants and immunosuppressants prohibited. Control group: Similar treatment without rhTM but no restriction of other drugs.                                     ([@b14-etm-0-0-8709])
  Sakamoto *et al* (2017)   Retrospective                          45            35            75.0±NR    75.0±NR     rhTM group: MP pulse therapy at 1 g/day for 3 days with cyclosporine A 2.5 mg/kg/day in 66 patients, followed by tapered dose of steroids and 0.06 mg/kg/day rhTM for 6 days. Control group: Similar treatment without rhTM. Furthermore, 11 patients received LMWH 75 IU for 14 days.                                           ([@b22-etm-0-0-8709])
  Arai *et al* (2019)       Prospective with historical controls   39            61            74.0±NR    74.0±NR     rhTM group: Generally treated with IV MP for 3 days. Polymyxin B-immobilized fibre column therapy administered using toraymyxin. Anticoagulant and antiplatelet drugs used as required. rhTM (380 U/kg/day) for 6 days. Control group:Similar treatment without rhTM.                                                            ([@b23-etm-0-0-8709])

rhTM, recombinant human soluble thrombomodulin; NR, not reported; MP, methylprednisolone; LMWH, low-molecular-weight heparin; IU, international units; IV, intravenous; SD, standard deviation.

###### 

Baseline characteristics of participants of the studies included.

                         Tsushima *et al* ([@b15-etm-0-0-8709])   Kataoka *et al* ([@b13-etm-0-0-8709])   Abe *et al* ([@b24-etm-0-0-8709])   Hayakawa *et al* ([@b14-etm-0-0-8709])   Sakamoto *et al* ([@b22-etm-0-0-8709])   Arai *et al* ([@b23-etm-0-0-8709])                                                                 
  ---------------------- ---------------------------------------- --------------------------------------- ----------------------------------- ---------------------------------------- ---------------------------------------- ------------------------------------ ----------- ------------- ----------- ----------- ----------- ----------
  PaO~2~/FiO~2~ (mmHg)   NR                                       NR                                      224.0±NR                            238.0±NR                                 198.0±62                                 234.0±126                            168.0±56    183.0±47      256.0±NR    260.0±NR    161.0±NR    194.6±NR
  WBC count, (mm^3^)     14,000±462                               15,820±291                              10,350±NR                           10,350±NR                                14,590±6,031                             9,518±2,835                          NR          NR            10,500±NR   10,200±NR   10,200±NR   9,700±NR
  LDH (IU/l)             782±41                                   477±13                                  300±NR                              313±NR                                   430±148                                  419±150                              378±118     444±173       353±NR      351±NR      349±NR      347±NR
  CRP (mg/dl)            13.1±0.7                                 11.8±0.5                                4.7±NR                              6.8±NR                                   6.8±5.8                                  11.3±7.3                             11.5±8.3    11±11.1       6.0±NR      6.9±NR      12.4±NR     9.1±NR
  KL-6 (U/l)             1,812±111                                1,956±218                               1,278±NR                            1,255±NR                                 2,018±780                                1,489±1,385                          1,512±583   2,060±1,520   1,299±NR    1,038±NR    1,192±NR    1,516±NR
  SP-D (ng/ml)           NR                                       NR                                      202±NR                              203±NR                                   759±638                                  338±338                              482±527     676±711       288±NR      317±NR      NR          NR
  D-dimer (mg/ml)        NR                                       NR                                      2.3±NR                              2.4±NR                                   4.4±3.7                                  3.3±4.9                              5.3±7.9     6.9±8.9       4.2±NR      4.8±NR      NR          NR
  TAT (ng/ml)            34.7±1.4                                 24.2±2.2                                NR                                  NR                                       9.1±11.0                                 14.8±22.7                            8.1±13.5    NR            NR          NR          NR          NR
  FDP (*μ*g/ml)          99.0±11.0                                39.6±7.4                                NR                                  NR                                       8.6±4.7                                  8.4±5.6                              NR          NR            8.8±NR      9.4±NR      NR          NR
  PIC (ng/ml)            NR                                       NR                                      NR                                  NR                                       1.4±0.4                                  1.8±0.7                              3.0±5.1     NR            NR          NR          NR          NR

rhTM, recombinant human soluble thrombomodulin; PaO~2~, oxygen partial pressure; FiO~2~, fraction of inspired oxygen; NR, not reported; WBC, white blood cell; LDH, lactate dehydrogenase; CRP, C-reactive protein; KL-6, Krebs von den Lungen-6; SP-D, surfactant protein D; TAT, thrombin-antithrombin; FDP, fibrin/fibrinogen degradation products; PIC, plasmin-α 2-plasmin inhibitor complex. Data presented as mean ± SD.

###### 

Adverse events reported by the studies included.

  Study              rhTM                                                                                                                                                                                                                              Control                                                                                                                                                                                                                                                                           (Ref.)
  ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------
  Tsushima *et al*   NR                                                                                                                                                                                                                                NR                                                                                                                                                                                                                                                                                ([@b15-etm-0-0-8709])
  Kataoka *et al*    One case of hemosputum on day 5. and one case of acute DVT on day 4.                                                                                                                                                              One case of bleeding from central venous catheter on day 3 and 1 case of subcutaneous bleeding on day 8.                                                                                                                                                                          ([@b13-etm-0-0-8709])
  Abe *et al*        One patient died of hepatic and renal failure due to high concentration of cyclosporine (suspected drug interaction with warfarin).                                                                                               None.                                                                                                                                                                                                                                                                             ([@b24-etm-0-0-8709])
  Hayakawa *et al*   None.                                                                                                                                                                                                                             None.                                                                                                                                                                                                                                                                             ([@b14-etm-0-0-8709])
  Sakamoto *et al*   Mild hemoptysis and hematuria in one patient on day 1. No case of serious bleeding.                                                                                                                                               None.                                                                                                                                                                                                                                                                             ([@b22-etm-0-0-8709])
  Arai *et al*       One case of gastrointestinal bleeding, one case of nasal bleeding, one case of DVT, one case of cerebral infarction, one case of drug-induced hepatitis, 1 case of an unspecified vascular event, one case of fungal infection.   Two cases of pneumomediastinum, one case of pneumothorax, three cases of DVT, one case of hepatitis B, one case of hepatitis B PCR positive, one case of sulfamethoxazole/trimethoprim, -associated thrombocytopenia, one case of MRSA pneumonia, one case of fungal infection.   ([@b23-etm-0-0-8709])

rhTM, recombinant human soluble thrombomodulin; NR, not reported; DVT, deep vein thrombosis; MRSA, methicillin-resistant Staphylococcus aureus.

###### 

Risk of bias summary.

  Study              Selection of participants   Confounding variables   Measurement of exposure   Blinding of outcome assessment   Incomplete outcome data   Selective outcome reporting   (Ref.)
  ------------------ --------------------------- ----------------------- ------------------------- -------------------------------- ------------------------- ----------------------------- -----------------------
  Tsushima *et al*   High risk                   High risk               Low risk                  Low risk                         Low risk                  Low risk                      ([@b15-etm-0-0-8709])
  Kataoka *et al*    High risk                   Low risk                Low risk                  Low risk                         Low risk                  Low risk                      ([@b13-etm-0-0-8709])
  Abe *et al*        High risk                   Low risk                Low risk                  Low risk                         Low risk                  Low risk                      ([@b24-etm-0-0-8709])
  Hayakawa *et al*   High risk                   High risk               Low risk                  Low risk                         Low risk                  Low risk                      ([@b14-etm-0-0-8709])
  Sakamoto *et al*   High risk                   Low risk                Low risk                  Low risk                         Low risk                  Low risk                      ([@b22-etm-0-0-8709])
  Arai *et al*       High risk                   Low risk                Low risk                  Low risk                         Low risk                  Low risk                      ([@b23-etm-0-0-8709])
